Back to Results
First PageMeta Content
Orphan drugs / Immunosuppressants / Proteobacteria / Eculizumab / Meningococcal disease / Alexion Pharmaceuticals / Neisseria meningitidis / Neisseria / Paroxysmal nocturnal hemoglobinuria / Bacteria / Medicine / Health


[removed]SOLIRIS® (eculizumab) Humanized First in Class Anti - C5 Antibody Human Framework Regions • No mutations
Add to Reading List

Document Date: 2014-07-24 09:35:18


Open Document

File Size: 1,65 MB

Share Result on Facebook

Company

Brodsky / Alexion Pharmaceuticals / /

Event

FDA Phase / /

Facility

Taiwan University of Pennsylvania / /

IndustryTerm

insurance experience / healthcare / healthcare professional / /

MedicalCondition

Insomnia / meningococcal infections / JE / Influenza-like illness / disease / Headache / Nasopharyngitis / Dyspnea / serious meningococcal infections / meningococcal meningitis / Nausea / paroxysmal nocturnal hemoglobinuria / thrombocytopenia / Herpes / concomitant bone marrow dysfunction / Fatigue / simplex virus infections / Meningococcal infection / Diarrhea / fatal meningococcal infections / INFECTION / Sinusitis / Cough / Constipation / thrombosis / infections / Back pain / Other infections / systemic infection / systemic infection SOLIRIS / /

MedicalTreatment

antibiotics / blood transfusion / vaccination / /

MusicGroup

Nausea / /

Organization

University of Pennsylvania / /

Person

Case Managers / Jack Goldberg / /

/

Position

Nurse / Professor of Medicine / /

Product

SOLIRIS / CH3 SOLIRIS® / /

URL

www.pnhsource.com / /

SocialTag